Interviews
View More
Bringing Cancer Screenings to the Community Can Increase Today's Diagnosis Number and Get Patients to Care Sooner

In this final video of a three-part video series, Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, shares a key takeaway from Quest's recent Health Trends Survey. Results reveal how cancer diagnosis numbers are still lagging to pre-pandemic levels of 11%. Fesko adds that bringing cancer screenings to the community can increase diagnosis numbers, leading to care sooner.

What the 'Pathway Approach' Can Do to Improve Health Outcomes, Reduce Testing Delays For Cancer Care

Dr. Yuri Fesko of Quest Diagnostics says the "pathways approach" helped one health system speed the time between diagnosis and targeted treatment for lung cancer by as much as a month for some patients. This is the second part of a three-part video series.

The Role of Switching and Combination Therapy in SMA Regimens

Medical experts provide insights on factors impacting SMA treatment strategies.

The Outcomes of Shortening the Gap on Time of Care After Receiving a Diagnosis

Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, talks about why shortening this gap is critical to ensuring better patient outcomes and shared steps hospitals, health systems and physicians can take now to reduce testing delays, improve outcomes and lower costs of care. This is the first part of a three-part video series.

Lack of Guidelines Impacting Demodex Blepharitis Treatment Landscape

A lack of guidelines impair the management of Demodex blepharitis.

Optimizing Treatment of SMA With Disease-Modifying Agents

Disease-modifying treatments are highlighted as key contributors to the optimization of SMA management.

Approach to Treatment Selection for Patients with SMA

Medical experts illustrate characteristics in the presentation of lupus nephritis.

Economic Burden and Quality of Life Impact Associated with Demodex Blepharitis

Douglas K. Devries, OD, discusses how Demodex blepharitis affects patients’ quality of life and associated financial burden.

Economic Burden of SMA

Julie Parsons, M.D., and John Brandsema, M.D., explore economic burdens associated with SMA.

Official Media Partners

PBMI logo

Join the Community

an mjh life sciences brand

© 2022 MJH Life Sciences and PBMI. All rights reserved.